Biotech Values

[jq1234]

Interview Head of Roche Pharma Research and Early Development

[Return to antibiotics: Interesting!]

There will also be more deals for antibiotics, a field in which pRED is looking to mount a return with programs that are pathogen-specific, linked to companion diagnostics and focused on hospital-based infections, like a life-threatening case of hospital-acquired pneumonia. And they're more likely to be IV-delivered than oral, with the kind of commercial potential that makes the work worthwhile to a company like Roche.

http://www.fiercebiotech.com/special-reports/john-reed-sets-out-long-distance-run-roches-pred